Melatonin prolonged-release · Circadin
Unknown / undisclosed
Evidence outlook
Approved: monotherapy for the short-term treatment of primary insomnia characterised by poor... (EU)
This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
Also approved (1)
- Circadin is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01906866 NCT01906866 · Sleep Disorders The trial randomized 125 children to double-blind Circadin or placebo, with 58 and 61 participants included in the primary efficacy analysis. The primary clinical sleep endpoint was met: Circadin increased total sleep time by 32.32 minutes versus placebo (p=0.035), supporting strong evidence despite the reported safety findings. Registry: NCT01906866 | 3 | Total Sleep Time (TST) (13 weeks) 2018-03-27 | Total Sleep Time (TST) (13 weeks): Circadin 2/5/10 mg 51.03 minutes (95% CI 30.3 to 71.76) vs Placebo 18.71 minutes (95% CI -2.73 to 40.15) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Phase 4 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other Melatonin receptor (MT1/MT2) drugs
tasimelteon. Compare all 2 Melatonin receptor (MT1/MT2) drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Melatonin Prolonged-Release (Circadin): this drug | Phase 3 | — | Melatonin receptor (MT1/MT2) | Reliable signal | NCT01906866: Total Sleep Time (TST) (13 weeks): Circadin 2/5/10 mg 51.03 minutes (95% CI 30.3 to 71.76) vs Placebo 18.71 minutes (95% CI -2.73 to 40.15) | |
| Tasimelteon (Hetlioz) | Approved(overall) | Small molecule | Melatonin receptor (MT1/MT2) | Partial signal | NCT01430754: RESET randomized withdrawal: maintenance of entrainment, continued tasimelteon vs withdrawal to placebo: 9/10 (90%) vs 2/10 (20%), difference 70% (95% CI 26.4 to 100.0), p=0.0026 (Lockley et al., Lancet 2015). |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Circadin (Melatonin prolonged-release) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.